AU3119995A - Treatment of cancer using hsv mutant - Google Patents

Treatment of cancer using hsv mutant

Info

Publication number
AU3119995A
AU3119995A AU31199/95A AU3119995A AU3119995A AU 3119995 A AU3119995 A AU 3119995A AU 31199/95 A AU31199/95 A AU 31199/95A AU 3119995 A AU3119995 A AU 3119995A AU 3119995 A AU3119995 A AU 3119995A
Authority
AU
Australia
Prior art keywords
cancer
mutant
treatment
gamma
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31199/95A
Other languages
English (en)
Inventor
Susanne Moira Brown
Nigel William Fraser
Alasdair Roderick Maclean
Bruce Paul Randazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Wistar Institute of Anatomy and Biology
Original Assignee
Medical Research Council
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU3119995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council, Wistar Institute of Anatomy and Biology filed Critical Medical Research Council
Publication of AU3119995A publication Critical patent/AU3119995A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU31199/95A 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant Abandoned AU3119995A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment
GB9415320 1994-07-29
PCT/GB1995/001791 WO1996003997A2 (fr) 1994-07-29 1995-07-28 Traitement du cancer a l'aide d'un mutant du virus de l'herpes (hsv)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU48720/99A Division AU752853B2 (en) 1994-07-29 1999-09-15 Treatment of cancer using HSV mutant

Publications (1)

Publication Number Publication Date
AU3119995A true AU3119995A (en) 1996-03-04

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31199/95A Abandoned AU3119995A (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant

Country Status (12)

Country Link
US (3) US7674468B2 (fr)
EP (2) EP0773785B1 (fr)
JP (2) JP4321723B2 (fr)
AT (1) ATE219681T1 (fr)
AU (1) AU3119995A (fr)
CA (1) CA2196315C (fr)
DE (1) DE69527204T2 (fr)
DK (1) DK0773785T3 (fr)
ES (1) ES2179880T3 (fr)
GB (1) GB9415320D0 (fr)
PT (1) PT773785E (fr)
WO (1) WO1996003997A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
CA2383372C (fr) * 1999-08-31 2010-04-13 The General Hospital Corporation Reciblage du promoteur specifique de tumeur et/ou de cellule dans l'expression du gene gamma 34.5 de l'herpes
DE60041210D1 (de) 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2366608T3 (es) 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
NZ541951A (en) 2003-03-07 2008-03-28 Robarts Res Inst Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en) 2003-03-27 2009-03-26 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
CA2600675C (fr) 2005-03-07 2015-12-15 Robarts Research Institute Combinaison du virus du myxome et de la rapamycine utilisee dans un traitement therapeutique
CN102026645B (zh) 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
RU2751236C2 (ru) * 2016-04-22 2021-07-12 Иммвира Ко., Лимитед КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
JP2023540548A (ja) * 2020-09-04 2023-09-25 イノブストーン セラピューティクス リミテッド 抗腫瘍活性を有する化合物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (fr) * 1990-09-14 2002-11-26 Robert L. Martuza Destruction de cellules neoplasiques a l'aide d'un virus
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
ES2183811T3 (es) 1992-03-31 2003-04-01 Arch Dev Corp Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6139834A (en) 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2007026146A1 (fr) 2005-08-30 2007-03-08 Crusade Laboratories Limited Traitement a l'aide du virus herpes simplex
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
EP2016182B8 (fr) 2006-05-11 2015-09-02 Virttu Biologics Limited Virus herpès simplex mutant et matériaux et procédés permettant de le générer
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
WO1996003997A3 (fr) 1996-05-02
JP4321723B2 (ja) 2009-08-26
US20050260169A1 (en) 2005-11-24
EP0773785B1 (fr) 2002-06-26
WO1996003997A2 (fr) 1996-02-15
EP1192948A2 (fr) 2002-04-03
US7674468B2 (en) 2010-03-09
DE69527204T2 (de) 2003-02-20
US8067012B2 (en) 2011-11-29
DK0773785T3 (da) 2002-10-07
US20120141418A1 (en) 2012-06-07
EP1192948A3 (fr) 2002-09-04
CA2196315C (fr) 2010-02-09
GB9415320D0 (en) 1994-09-21
JP2008037869A (ja) 2008-02-21
JPH10503766A (ja) 1998-04-07
ES2179880T3 (es) 2003-02-01
EP0773785A2 (fr) 1997-05-21
PT773785E (pt) 2002-11-29
US20100172872A1 (en) 2010-07-08
CA2196315A1 (fr) 1996-02-15
DE69527204D1 (de) 2002-08-01
ATE219681T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
GB9415320D0 (en) Cancer treatment
AU676349B2 (en) Nucleic acid-binding oligomers possessing N-branching for therapy and diagnostics
LUC00032I2 (fr)
AU693410B2 (en) Optical source having a strongly scattering gain medium providing laser-like action
AU7423894A (en) A container for blood
AU2831895A (en) Electron-emitting device, electron source and image-forming apparatus using the device, and manufacture methods thereof
AU5554986A (en) Treatment of viral diseases with azolylmethyloxiranes
AU8262991A (en) Genetic mechanisms of tumor suppression
IL110284A0 (en) Viral vectors and their use in gene therapy
AU3636189A (en) Hiv-2 virus variants
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
AU632242B1 (en) Polymerization intitiator composition controlling polymerization at interface and curable composition containing same
AU7921894A (en) Full field mask illumination enhancement methods and apparatus
AU7161994A (en) nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics
EP0387821A3 (fr) 2-Alkyl-4-arylméthylaminoquinoléines, leur utilisation et médicaments les contenant
EP0613050A3 (fr) Photoréserve universel de type négatif.
AU9740598A (en) Foldable intra-ocular lens
HUT70218A (en) Process for the manufacture of (s)-3-amino-1-substituted-pyrrolidines
AU4363093A (en) Cycloaliphatic acrylic monomer
AU6243696A (en) Gene preparations
EP0658196A4 (fr) INSERTION GENIQUE PAR LIAISON -i(IN VITRO) DIRECTE.
MX9803953A (es) Peptidos novedosos, preparacion y uso de los mismos.
AU3512793A (en) Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use
AU3395993A (en) Process for the expression of herpes simplex virus type 1 glycoprotein E and methods of use
AU3019592A (en) A novel translational activating sequence